Biomarin Pharmaceutical (BMRN) Gains from Investment Securities (2012 - 2022)

Biomarin Pharmaceutical's Gains from Investment Securities history runs 11 years deep, the most recent figure standing at -$539000.0 for Q4 2022.

• Quarterly Gains from Investment Securities fell 130.42% year-over-year to -$539000.0 in Q4 2022, while the trailing twelve-month figure through Sep 2023 was -$539000.0 (down 113.42% YoY) and the FY2022 annual result came in at $1.7 million, down 78.77% from the prior year.
• Gains from Investment Securities was -$539000.0 for Q4 2022 at Biomarin Pharmaceutical, down from $905000.0 in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $12.3 million in Q1 2019 and bottomed at -$7.4 million in Q2 2019.
• A 5-year average of $1.4 million and a median of $1.3 million in 2021 frame the typical range for Gains from Investment Securities.
• Annual changes were most pronounced in 2018 — Gains from Investment Securities tumbled 165.1% — and 2021, when it soared 56475.0%.
• Biomarin Pharmaceutical's Gains from Investment Securities stood at -$3.5 million in 2018, then soared by 87.54% to -$441000.0 in 2019, then jumped by 813.83% to $3.1 million in 2020, then plunged by 43.71% to $1.8 million in 2021, then sank by 130.42% to -$539000.0 in 2022.
• Business Quant data shows BMRN's Gains from Investment Securities at -$539000.0 in Q4 2022, $905000.0 in Q3 2022, and -$651000.0 in Q2 2022.